1. Home
  2. LXRX vs SSYS Comparison

LXRX vs SSYS Comparison

Compare LXRX & SSYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LXRX

Lexicon Pharmaceuticals Inc.

HOLD

Current Price

$1.68

Market Cap

660.9M

Sector

Health Care

ML Signal

HOLD

Logo Stratasys Ltd. (Israel)

SSYS

Stratasys Ltd. (Israel)

HOLD

Current Price

$8.61

Market Cap

730.7M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
LXRX
SSYS
Founded
1995
1989
Country
United States
United States
Employees
N/A
1757
Industry
Biotechnology: Pharmaceutical Preparations
Computer peripheral equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
660.9M
730.7M
IPO Year
2000
2012

Fundamental Metrics

Financial Performance
Metric
LXRX
SSYS
Price
$1.68
$8.61
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
3
Target Price
$4.15
$12.33
AVG Volume (30 Days)
2.1M
525.0K
Earning Date
05-12-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
77.78
N/A
EPS
N/A
N/A
Revenue
$49,803,000.00
N/A
Revenue This Year
N/A
$4.48
Revenue Next Year
N/A
$3.23
P/E Ratio
N/A
N/A
Revenue Growth
60.24
N/A
52 Week Low
$0.51
$7.34
52 Week High
$1.95
$12.78

Technical Indicators

Market Signals
Indicator
LXRX
SSYS
Relative Strength Index (RSI) 47.92 52.61
Support Level $1.47 $8.55
Resistance Level $1.81 $8.97
Average True Range (ATR) 0.10 0.26
MACD -0.01 0.08
Stochastic Oscillator 31.25 67.98

Price Performance

Historical Comparison
LXRX
SSYS

About LXRX Lexicon Pharmaceuticals Inc.

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.

About SSYS Stratasys Ltd. (Israel)

Stratasys Ltd offers polymer-based 3D printing solutions for designers, engineers, manufacturers, dental and medical professionals, and others. Its 3D printing systems utilize the firm's patented extrusion-based FDM, inkjet-based PolyJet, powder-bed-based SAF, photopolymer-based P3, and Neo stereolithography technologies to enable the production of prototypes, tools, and manufactured goods directly from 3D CAD files or other 3D content. The company's solutions portfolio comprises 3D printing systems, consumables, software, paid parts, and professional services, allowing end-users to effectively print 3D models, tools, and parts. Geographically, it generates maximum revenue from the United States, followed by Europe, Middle East and Africa, Asia-Pacific, and other regions.

Share on Social Networks: